A drug for ALS or motor neuron disease received a green light from an FDA panel instead of waiting for further trial results. The unusual decision can be justified in this case, but such fast-tracking should be rare, says rob_cyran.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Scoop: Jif plant in Kentucky had a history of Salmonella, FDA records showFDA inspectors found that Jif officials had identified Salmonella at their plant in Lexington, Kentucky, a dozen times before a recent outbreak.
Weiterlesen »
In reversal, FDA panel votes to recommend experimental ALS drugIn an unusual move, the FDA advisory panel convened for the second time in less than a year to review Amylyx's drug for amyotrophic lateral sclerosis.
Weiterlesen »
FDA panel backs much-debated ALS drug in rare, 2nd reviewWASHINGTON (AP) — A panel of federal health advisers voted Wednesday to recommend approval for an experimental drug to treat Lou Gehrig’s disease, a remarkable turnaround for the much-debated medication that was previously rejected by the same group earlier this year.
Weiterlesen »
FDA Approves New Botox RivalThe U.S. Food and Drug Administration approved a new antiwrinkle treatment that could be the most formidable challenger to date to market leader Botox
Weiterlesen »